These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1606527)

  • 21. Immunoglobulin therapy in Kawasaki syndrome and RSV prophylaxis.
    Meissner HC; Leung DY
    Front Biosci; 1996 Aug; 1():e55-64. PubMed ID: 9159245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous gammaglobulin, 2: Pharmacology, clinical uses and mechanisms of action.
    Schiff RI
    Pediatr Allergy Immunol; 1994 Aug; 5(3):127-56. PubMed ID: 7951755
    [No Abstract]   [Full Text] [Related]  

  • 23. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
    Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
    Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease.
    Shrestha S; Wiener HW; Olson AK; Edberg JC; Bowles NE; Patel H; Portman MA
    J Allergy Clin Immunol; 2011 Sep; 128(3):677-80. PubMed ID: 21601260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome].
    Marcinkiewicz J; Szymanowska Z; Mazurek A
    Przegl Lek; 1998; 55(11):611-3. PubMed ID: 10216377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Kawasaki disease--two case reports].
    Mroczkowska-Juchniewicz A; Moszyńska B; Pawłowska-Kamieniak A; Szczepanowska A; Papierkowski A
    Pol Merkur Lekarski; 1997 Jul; 3(13):20-1. PubMed ID: 9432293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
    Ye Q; Gong FQ; Shang SQ; Hu J
    Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
    Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT
    J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
    Saji T; Takatsuki S; Kobayashi T
    Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease.
    Tacke CE; Smits GP; van der Klis FR; Kuipers IM; Zaaijer HL; Kuijpers TW
    J Allergy Clin Immunol; 2013 Jun; 131(6):1701-3. PubMed ID: 23498596
    [No Abstract]   [Full Text] [Related]  

  • 31. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease.
    Weng KP; Hsieh KS; Ho TY; Huang SH; Lai CR; Chiu YT; Huang SC; Lin CC; Hwang YT; Ger LP
    Circ J; 2010 Mar; 74(3):544-51. PubMed ID: 20081319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
    Klassen TP; Rowe PC; Gafni A
    J Pediatr; 1993 Apr; 122(4):538-42. PubMed ID: 8463897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunology of Kawasaki disease.
    Arav-Boger R; Assia A; Jurgenson U; Spirer Z
    Adv Pediatr; 1994; 41():359-67. PubMed ID: 7992690
    [No Abstract]   [Full Text] [Related]  

  • 34. Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment.
    Schiller B; Elinder G
    Acta Paediatr; 1999 Aug; 88(8):844-8. PubMed ID: 10503683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological abnormalities and endothelial cell injury in Kawasaki disease.
    Nonoyama S
    Acta Paediatr Jpn; 1991 Dec; 33(6):752-5. PubMed ID: 1801555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for intravenous immunoglobulin therapy of Kawasaki disease.
    Shulman ST
    Pediatr Infect Dis J; 1992 Nov; 11(11):985-6. PubMed ID: 1454455
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Kawasaki disease.
    Glode MP; Burns JC
    Pediatr Infect Dis J; 1992 Mar; 11(3):249-50. PubMed ID: 1565549
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
    Shiraishi T; Yamamoto T
    Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.